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Hardening of the skin of the trunk and upper extremities 
without Raynaud’s phenomenon — a quiz
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Case report
A 64-year-old Caucasian male with a history of 
chronic obstructive pulmonary disease was admit-
ted to the Department of Dermatology, Venereology 
and Allergology in Wroclaw because of a 7-month 
history of progressive symmetrical skin thickening 
of the shoulders, forearms, chest and lateral sides 
of the trunk and lower limbs. Due to suspicion of 
systemic sclerosis the patient was hospitalized in the 
Department of Rheumatology and Internal Medicine 
in Wrocław. At that time the patient demonstrated 
skin hardening of the trunk and upper extremities 
(Fig. 1), however, without involvement of the face 
and hands. In addition, contractures and movement 
restriction in the elbow and shoulder joints without 
any signs of arthritis were noted. Nor Raynaud’s phe-
nomenon neither other systemic findings were obse-
rved. Laboratory examination revealed accelerated 
erythrocyte sedimentation rate (ESR) of 55 mm/h, 
peripheral blood eosinophilia (0.74 × 103/µL, N: < 0.6) 
and high C-reactive protein (CRP) concentration in 
the serum (41.44 mg/l, N: < 5.0). Nailfold capillaro-
scopy was normal and rheumatoid factor (RF) was 
not present. The patient started the treatment with 
azathioprine (100 mg/d p.o.) in combination with 
methylprednisolone (4 mg/d p.o.), however, no im-
provement was observed. Four months later, becau-
se of a lack of clinical improvement, the patient was 
hospitalized for the second time in the Department 
of Rheumatology and Internal Medicine. The labo-
ratory examination revealed a decrease of bioche-
mical markers of inflammation (ESR — 34 mm/h, 
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Figure 1A and 1 B. Clinical presentation of the patient
CRP — 4.25 mg/L), as well as normalization of blood 
eosinophilia (0.06 × 103/µL). During this stay the 
dose of azathioprine was increased to 150 mg/d, 
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A
Figure 2. Histological examination. A. A very mild eosinophilic 
infiltration around the small vessels in the dermis, plain dermo-
epidermal junction, and otherwise normal histology of epidermis 
and dermis; B. A dense inflammatory infiltrate of the deep 
fascia with scattered eosinophils; C. Larger magnification of 
inflammatory infiltrate of the fascia
Figure 3. Magnetic resonance imaging of the chest of the presented 
patient. Please note thickening and irregularity of the fascia on the right site
and the dose of methylprednisolone was mainta-
ined. However, dermatological consultation was 
also reco mmended. According to the suggestion 
of consulting dermatologist, a deep skin biopsy was 
performed. Histological examination of the speci-
men revealed a mild eosinophilic infiltration around 
the small blood vessels of the dermis and thickened 
fascia surrounded by a dense inflammatory infiltrate 
(Fig. 2). Magnetic resonance imaging (MRI) of the 
chest discovered subcutaneous hyperintense bands 
from the superior to inferior margin of the scapula 
suggestive of edema and inflammatory changes in 
the superficial part of the fascia (Fig. 3). 
WhAt is your diAgnosis?
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eosinophiliC FasCiitis 
On the basis of the clinical and histological findings 
the diagnosis of Shulman syndrome was established and 
systemic prednisone therapy was initiated at a dose of 
0.5 mg/kg/day, which resulted in a significant improvement 
of clinical condition of our patient. An in-depth diagnostic 
did not reveal any underlying condition, which might be 
related to observed symptoms. 
Eosinophilic fasciitis (EF), also known as Shulman syn-
drome or diffuse EF, is a rare inflammatory and fibrosing di-
sorder of the skin and fascia. Described in 1974 by Lawrence 
Shulman, this distinctive entity, has yet to unlock the many 
mysteries, including the etiology and pathophysiology. Sin-
ce its discovery, EF has been reported in over 300 cases [1]. 
EF tends to predominate in Caucasians but reports have 
also been made in Asians, African Americans and Africans 
[1]. Women are more often affected than men [1]. The age of 
the patients at the disease onset is widely varied and ranges 
from 1 to 88 years with the most cases being recognized at 
from the third to the sixth decade of life [1]. 
The etiology of Shulman syndrome is unknown, but 
researchers have proposed some possible triggers and as-
sociations. The hypothesis of an abnormal immune reaction 
has been formulated based on the presence of hypergam-
maglobulinemia and antinuclear antibodies (ANA) in some 
patients [2, 3]. Some researchers believe that EF is a subtype 
of scleroderma due to the characteristic hardening of the 
skin while others believe it falls in the category of fasciitis-
-panniculitis syndromes due to its characteristic hardening 
and thickening of the skin on the basis of chronic inflam-
mation [2]. Triggers that have been implicated with this 
disorder include drugs, such as simvastatin or phenytoin, 
and other environmental factors such as Borrelia burgdorferi 
infection, excessive exercise in subjects who are usually 
not very physically active, prolonged exposure to a cold 
environment and trauma. These triggers are thought to 
an abnormal response leading to an accumulation of eosi-
nophils and other leukocytes in different areas of the body 
[2]. Some cases might have been related to L-tryptophan as 
the epidemic of EF was seen in 1982 [2]. 
The onset of EF is usually sudden, developing in a range 
of days to weeks, while less common variants may be more 
gradual. Both share an initial presentation of symmetrical 
pain, inflammation and non-pitting edema affecting the 
arms and forearms more commonly than the thighs and 
legs. On rare occasions the face, neck, buttocks, abdomen 
and chest may be involved as well. One may see venous 
grooving, a shallow furrow seen from the underlying veins, 
as the skin begins to change as well as peau d’orange. In its 
natural course, the disease initially presents with features 
of acute skin inflammation such as erythema and warmth 
of the affected area. It is followed by skin induration and 
finally skin fibrosis is observed. If the disease progresses, 
dermatogenic contractures may develop affecting the qu-
ality of life (QoL). Some patients may present with malaise, 
asthenia, arthritis and myalgia. Carpal tunnel syndrome 
(CTS) has also been documented due to the compression 
of the median nerve. Internal organ involvement, usually 
of mild severity, is an uncommon feature of EF [2]. The 
characteristic features of Shulman syndrome are described 
in Table 1.
Peripheral blood eosinophilia is seen in about 61–83%, 
hypergammaglobulinemia in 18–67% and elevated ERS 
in 29–70% of the affected individuals [1]. RF and ANA are 
usually absent, but may be present on rare occasions. Tissue 
inhibitor of metalloproteinase 1 (TIMP-1) is a new serological 
marker found in patients with active disease [1]. The imaging 
method of choice is MRI. The characteristic findings on MRI 
include fascial thickening with abnormal signal intensity and 
contrast enhancement with gadolinium [1, 4]. To establish 
the definitive histological diagnosis, deep incisional biopsy 
containing skin, fatty tissue, fascia and superficial muscles 
is necessary. Histopathological hallmarks are inflammation, 
thickening, edema and sclerosis of the fascia. Other findings 
include infiltration of the deep fascia from plasma cells, lym-
phocytes, eosinophils and histiocytes as well as hyalinized 
collagen bands running parallel to the fascia [1].
Treatment depends on the severity of the disease. In 
some cases, EF resolves spontaneously. However, in most pa-
tients high-dose prednisone gradually tapered is considered 
as the first line treatment [5]. Other therapies such as surgical 
decompression of CTS, surgical release of the contracture 
and non-steroidal anti-inflammatory drugs for analgesia 
should be considered if necessary [2]. Unfortunately, in 
certain cases, the disease may be refractory to the corticoste-
roid therapy [5]. As an alternative, other immunosuppressive 
drugs like mycophenolate mofetil or methotrexate should 
be considered [5]. Of note, Khanna et al. [6] documented 
a very good effect of a therapy with monoclonal TNF-alpha 
inhibitor, while Bukiej et al. [7] showed significant improve-
ment of steroid-resistant EF after cyclosporine A course. 
Furthermore, Lebeaux et al. [5] described positive results of 
treatment with methotrexate, azathioprine and rituximab. 
Considering the current insights on disease’s pathogenesis, 
it seems reasonable to determine the efficacy of treatment 
table 1. Features of eosinophilic fasciitis (Shulman syndrome)
Symmetrical hardening of the skin and subcutaneous tissue
Peripheral and tissue eosinophilia 
Hypergammaglobulinemia
Elevation of erythrocyte sedimentation rate
Inflammation and fibrosis of the fascia with eosinophilic, 
lymphocytic and plasmacytic infiltrate 
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with interleukin-5 inhibitors such as mepolizumab, benrali-
zumab or reslizumab [8, 9]. 
Summarizing, the main rationale for our case presenta-
tion was a relatively small number of EF descriptions found 
in the literature. In the described case the lack of internal 
organ involvement and the absence of Raynaud’s phenom-
enon were helpful differentiation features from systemic 
sclerosis. We hope that, with the surging advancement of 
understanding of Shulman syndrome, early recognition, 
adequate therapeutic management and patient education 
may prolong the remission, decrease the risk of comorbidi-
ties and improve the patients’ QoL. 
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